JP2021510723A - 吸入型治療薬の高用量送達 - Google Patents

吸入型治療薬の高用量送達 Download PDF

Info

Publication number
JP2021510723A
JP2021510723A JP2020540345A JP2020540345A JP2021510723A JP 2021510723 A JP2021510723 A JP 2021510723A JP 2020540345 A JP2020540345 A JP 2020540345A JP 2020540345 A JP2020540345 A JP 2020540345A JP 2021510723 A JP2021510723 A JP 2021510723A
Authority
JP
Japan
Prior art keywords
powder
particles
shell
density
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510723A5 (enExample
Inventor
ソン，ヨン−ジュ
フアン，ダニエル
ミラー，ダンフォース
ウィアース，ジェフリー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021510723A publication Critical patent/JP2021510723A/ja
Publication of JP2021510723A5 publication Critical patent/JP2021510723A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020540345A 2018-01-26 2019-01-24 吸入型治療薬の高用量送達 Pending JP2021510723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622464P 2018-01-26 2018-01-26
US62/622,464 2018-01-26
PCT/IB2019/050607 WO2019145897A1 (en) 2018-01-26 2019-01-24 High dose delivery of inhaled therapeutics

Publications (2)

Publication Number Publication Date
JP2021510723A true JP2021510723A (ja) 2021-04-30
JP2021510723A5 JP2021510723A5 (enExample) 2022-01-19

Family

ID=65635769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540345A Pending JP2021510723A (ja) 2018-01-26 2019-01-24 吸入型治療薬の高用量送達

Country Status (14)

Country Link
US (1) US20210069106A1 (enExample)
EP (1) EP3743045A1 (enExample)
JP (1) JP2021510723A (enExample)
KR (1) KR20200115560A (enExample)
CN (1) CN111526870A (enExample)
AR (1) AR114308A1 (enExample)
AU (2) AU2019212586C1 (enExample)
BR (1) BR112020014793A2 (enExample)
CA (1) CA3089439A1 (enExample)
CL (1) CL2020001939A1 (enExample)
IL (1) IL276241A (enExample)
MX (1) MX2020007745A (enExample)
RU (1) RU2020127882A (enExample)
WO (1) WO2019145897A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
WO2026082944A1 (en) 2024-10-17 2026-04-23 Hovione Farmaciência S.A. High-density composite active particles comprising beta-lactoglobulin and api, compositions comprising same, and methods for the manufacture thereof
CN119306869B (zh) * 2024-12-13 2025-05-16 万华化学集团股份有限公司 一种乙烯/α-烯烃共聚物及其制备方法、采用其的封装胶膜

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510824A (ja) * 2004-08-23 2008-04-10 マンカインド コーポレイション 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
JP2009544716A (ja) * 2006-07-27 2009-12-17 ノバルティス アクチエンゲゼルシャフト 肺送達のためのインスリン含有エアロゾル化可能製剤
WO2012106575A1 (en) * 2011-02-04 2012-08-09 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
JP2015509788A (ja) * 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
US20160030596A1 (en) * 2013-03-15 2016-02-04 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
US20170066823A1 (en) * 2015-09-09 2017-03-09 Matthew John EDWARDS Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
WO2017042696A1 (en) * 2015-09-09 2017-03-16 Novartis Ag Targeted delivery of spray-dried formulations to the lungs
WO2017125853A1 (en) * 2016-01-19 2017-07-27 Novartis Ag Multidose inhaler
US20170216538A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry Powder Inhaler

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992335A1 (en) 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
KR20050088243A (ko) 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
TR200907236A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz formülasyonunun blister ambalajda taşınması.

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510824A (ja) * 2004-08-23 2008-04-10 マンカインド コーポレイション 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
JP2009544716A (ja) * 2006-07-27 2009-12-17 ノバルティス アクチエンゲゼルシャフト 肺送達のためのインスリン含有エアロゾル化可能製剤
WO2012106575A1 (en) * 2011-02-04 2012-08-09 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
JP2014507432A (ja) * 2011-02-04 2014-03-27 ノバルティス アーゲー 閉塞性または炎症性気道疾患を治療するための２種以上の活性成分を含有する粒子の乾燥粉末製剤
JP2015509788A (ja) * 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
US20150136130A1 (en) * 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
US20160030596A1 (en) * 2013-03-15 2016-02-04 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
US20170066823A1 (en) * 2015-09-09 2017-03-09 Matthew John EDWARDS Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
WO2017042696A1 (en) * 2015-09-09 2017-03-16 Novartis Ag Targeted delivery of spray-dried formulations to the lungs
WO2017125853A1 (en) * 2016-01-19 2017-07-27 Novartis Ag Multidose inhaler
US20170216538A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry Powder Inhaler

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID LECHUGA-BALLESTEROS ET AL: "Trileucine Improves Aerosol Performance and Stability of Spray-Dried Powders for Inhalation", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, no. 1, JPN7022005594, January 2008 (2008-01-01), pages 287 - 302, ISSN: 0004937693 *

Also Published As

Publication number Publication date
AR114308A1 (es) 2020-08-19
KR20200115560A (ko) 2020-10-07
AU2019212586C1 (en) 2022-04-28
RU2020127882A (ru) 2022-02-28
AU2019212586A1 (en) 2020-07-09
US20210069106A1 (en) 2021-03-11
MX2020007745A (es) 2020-09-25
EP3743045A1 (en) 2020-12-02
CA3089439A1 (en) 2019-08-01
CN111526870A (zh) 2020-08-11
IL276241A (en) 2020-09-30
CL2020001939A1 (es) 2021-01-04
AU2019212586B2 (en) 2022-01-06
BR112020014793A2 (pt) 2020-12-08
WO2019145897A1 (en) 2019-08-01
RU2020127882A3 (enExample) 2022-02-28
AU2022202278A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
JP6669808B2 (ja) 超低密度肺粉剤
CN103998087B (zh) 用于吸入分布独立性给药的雾化装置
CN100522142C (zh) 对生产过程中的湿度进行控制以生产较大的多孔微粒
JP7048642B2 (ja) 肺、鼻、舌下および／または咽頭への送達に適した、少なくとも１つの生物活性化合物をロードした多孔質シリカ粒子の製造方法
JP4384503B2 (ja) レボドパの肺送達
CN110996912A (zh) 用于鼻内递送的干粉组合物
AU2022202278A1 (en) High Dose Delivery of Inhaled Therapeutics
JP7077219B2 (ja) 噴霧乾燥製剤の肺への標的化送達
Yeung et al. Dosing challenges in respiratory therapies
EP3727418B1 (en) Surfactant formulations for inhalation
JP7335263B2 (ja) 吸入のための界面活性剤製剤
JP2025511232A (ja) 吸入複合体及び担体ベースの製剤の組合せ
HK40064779A (en) Novel carrier particles for dry powder formulations for inhalation
HK40014165A (en) A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704